Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.7450 (-0.17%) ($5.7450 - $5.7450) on Wed. Aug. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.05% (three month average) | RSI | 61 | Latest Price | $5.7450(-0.17%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.9% a day on average for past five trading days. | Weekly Trend | AUTL advances 1.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(55%) ARKG(50%) ARKK(49%) IWO(49%) ACES(48%) | Factors Impacting AUTL price | AUTL will decline at least -2.025% in a week (0% probabilities). VIXM(-32%) VXX(-30%) SHY(-19%) TLT(-17%) XLU(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.025% (StdDev 4.05%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.76 | 5 Day Moving Average | $5.82(-1.29%) | 10 Day Moving Average | $5.93(-3.12%) | 20 Day Moving Average | $5.76(-0.26%) | To recent high | -27.6% | To recent low | 8.1% | Market Cap | $300m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |